DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays AJ Rice - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Joanna Gajuk - Bank of America Ryan Langston - TD Cowen Justin Lake - Wolfe Research Operator Good evening. My name is Michelle and I will be your conference facilitator today.
DaVita HealthCare (DVA) Q3 Earnings Miss Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago.
DaVita misses third-quarter profit estimates on higher costs
DaVita reported third-quarter profit that missed Wall Street estimates on Tuesday, hurt by high patient care costs.
6 Stocks Dominate Market's 'Best 6 Months' — Starting This Week
If you had to choose the best time to invest in the S&P 500 — it's the six months starting in November.
DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?
Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
DaVita HealthCare (DVA) concluded the recent trading session at $163.16, signifying a +1% move from its prior day's close.
DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts
In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.
Can DaVita Stock Continue Its Bull Run After Doubling in a Year?
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Investors Undervaluing DaVita (DVA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?
DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.
Here's Why You Should Add DaVita Stock to Your Portfolio Now
DVA's strength in its kidney care business raises optimism about the stock.
